Currently there are 26 ongoing clinical trials to assess the use of CAR-T cell therapies in AML, including 12 that are specifically for anti-CD123 CAR-T, 5 for anti-CD33 CAR-T, and 3 that are investigating CAR-T cells that target multiple antigens (clinicaltrials.gov). This evidence concerns the gene IL3RA and acute myeloid leukemia.